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Available online xxxxBackground & Aims: Recent studies documented an increased cardiovascular risk in patients with inﬂammatory
bowel disease (IBD). Our study aimed at investigating the prevalence of intima-media thickness (IMT) of the
carotid arteries and the arterial stiffness indices as markers of early atherosclerosis in young IBD patients.
Methods: We recruited 68 consecutive IBD patients, and 38 matched healthy controls less than 45 years old
(median age 31.6 ± 8.1 years). Clinical and demographic features, cardiovascular risk factors, history of
cardiovascular events, concomitant therapies were registered on a dedicate database. Carotid IMTwas evaluated
by using high resolution B-mode ultrasonography. Arterial stiffness was assessed by measurement of carotid-
femoral Pulse Wave Velocity (PWV) and Augmentation Index (AIx).
Results: Total cholesterol (P b 0.013) and LDL-cholesterol (P b 0.019) levels were signiﬁcantly lower in IBD pa-
tients compared to controls. Carotid IMT was higher in IBD than in controls (P b 0.047), but there was no statis-
tically signiﬁcant difference among Crohn's Disease (CD) and Ulcerative Colitis (UC) patients. Moreover, PWV
and AIx were signiﬁcantly higher in patients as compared to controls (P b 0.006 and P b 0.004 respectively).
No medication seemed to affect vascular measurements, though stiffness parameters were signiﬁcantly higher
in patients treated with 5-ASA (11.9 (9.7) vs 18.2 (10.2), P b 0.021), suggesting a lack of efﬁcacy of 5-ASA in
protecting IBD patients from early atherogenesis.
Conclusions:Young IBD patients show an increase in subclinicalmarkers of atherosclerosis. Future studies need to
address whether these markers result in an increased risk of cardiovascular events in these patient.
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
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Inﬂammatory bowel diseases (IBD), Crohn's Disease (CD) and
Ulcerative Colitis (UC), are chronic inﬂammatory disorders of the
gastrointestinal tract. Pathogenesis may be the result of interaction
between environmental factors and intestinal bacteria in genetically
predisposed individuals, which may give rise to an aberrant immune
response leading to bowel damage [1].Crohn's Disease; UC, Ulcerative
e velocity; AIx, Augmentation
pressure; FMD, Flow mediated
tive protein.
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creased expression of marker
.1016/j.ejim.2016.10.004Several studies have investigated the association between IBD,
cardiovascular and thromboembolic disease [2–3]. Recently, re-
searchers have focused on cardiovascular risk and on the possibility of
early onset and rapid progression of the atherosclerotic process, with
conﬂicting results [4–9].
Atherosclerosis is a pathological condition mainly characterized by
loss of elasticity of arterialwalls. Atherogenesis is a chronic inﬂammato-
ry process of the arterial wall, ﬁnally leading to endothelial dysfunction
[10,11], which involves the alteration of the control of the vascular tone,
leukocytes trafﬁcking and platelets adhesion. The risk of early onset of
atherosclerosis is well known in individuals suffering from other
chronic inﬂammatory disorders such as rheumatoid arthritis and
systemic lupus erythematosus [12–14], thus it should not be surprising
that, in the last decade, an increasing body of data, both epidemiological
and clinical, have supported this association also in IBD.
Epidemiological studies on incidence of cardiovascular events in pa-
tients with IBD have led to discrepant results [15–19]. A retrospectivehts reserved.
s of early atherosclerosis in patients with inﬂammatory bowel disease,
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artery disease in patients with IBD was higher as compared to a control
group, in spite of a low incidence of traditional risk factors (smoking,
diabetes, hypertension and hypercholesterolemia). Two Danish
nation-wide cohort studies demonstrated an increased risk of ischemic
heart disease and also showed that the risk was lower in those treated
with 5-ASA [17,20]. Finally, a systematic review has conﬁrmed the key
role of chronic inﬂammation in causing progression of the atheroscle-
rotic process and thus, coronary risk in IBD [19].
From a clinical point of view, the assessment of early atherosclerosis
has been made by investigating surrogate markers such as the carotid
artery intima-media thickness (IMT), ﬂow-mediated vasodilatation of
the brachial artery (FMD) and arterial stiffness by pulse wave velocity
(PWV) [21–30]. The study by Aloi et coll, reported signs of endothelial
dysfunction and early atherosclerosis even in children with IBD [27].
Zanoli et al. reported results from two studies [29,30] carried on IBD
adult patients evaluated by measuring arterial stiffness, the ﬁrst being
a cross-sectional study, the second evaluating the effect of long-term
therapy. Both studies showed that there was an increase in both
carotid-radial and carotid-femoral PWV in IBD patients as compared
with controls and that arterial stiffness of these patients was related to
the degree of inﬂammation and reduced by immunomodulatory
drugs.More recently, Ozturk et al. [31] added further evidence to the as-
sociation of early atherosclerosis markers and IBD by investigating arte-
rial stiffness, FMD and IMT, showing a signiﬁcant relationship between
disease duration and hemodynamic parameters.
In the current cross-sectional study, we aimed to demonstrate in a
homogeneous prospective Mediterranean cohort of young IBD patients
(aged less than 45 years) early signs of atherosclerosis through the
assessment of IMT of the carotid arteries and of arterial stiffness studied
by PWV and Augmentation Index (AIx). Furthermore, we tried to
evaluatewhether 5-aminosalicilyc acids (5-ASA), steroids, immunosup-
pressant drugs and biologics could affect hemodynamic parameters.
2. Materials and methods
2.1. Patient's selection
One hundred-six subjects aged between 17 and 45 years have been
enrolled from September 2012 until December 2013; sixty-eight were
patients consecutively diagnosed as suffering from IBD and attending
our IBD outpatient clinic and 38 were healthy individuals enrolled as
age and sex-matched controls. Written informed consent for participa-
tion in the study was obtained from both patients and controls.
Clinical and demographic datawere recorded in a dedicated database.
Clinical data included: age, gender, family history of IBD, co-morbidities,
(e.g. diabetes and/or hypertension), traditional risk factors for the onset
of atherosclerosis (Blood Pressure, Body Mass Index, smoking, Total-
Cholesterol, Triglycerides, LDL-Cholesterol, HDL-Cholesterol), disease
features (IBD type, extent, extra-intestinal manifestations, previous
surgery), disease activity assessed by Mayo Score [32] for UC and the
Harvey Bradshaw Index for CD [33], C-reactive protein (CRP) values,
concomitant drug therapies. A blood sample was drawn for the
evaluation of lipid proﬁle and other laboratory parameters.
On recruitment, traditional risk factorswere evaluated for both cases
and controls on the basis of the criteria shown below. Smoking habit
was explored and recorded in the database. Hypercholesterolemia was
deﬁned as the presence of total cholesterol blood levels ≥ 200 mg/dL.
Hypertension was deﬁned as present, if subjects has been previously
diagnosed according to the World Health Organization/International
Society of Hypertension guidelines and were routinely receiving anti-
hypertensive therapy. Patients were deﬁned as type 2 diabetics if they
had diabetes treated by diet, or if they were taking oral hypoglycemic
drugs or insulin. Individuals with already known cardiovascular disease
(coronary heart disease, stroke, transient ischemia attack) were
excluded.Please cite this article as: Cappello M, et al, Increased expression of marker
Eur J Intern Med (2016), http://dx.doi.org/10.1016/j.ejim.2016.10.004Standard laboratory parameters, including CRP and erythrocyte-
sedimentation rate (ESR), were measured in the blood at time of
hemodynamic measurements. All participants were evaluated in a
quiet room, where non-invasive assessment of hemodynamic parame-
ters was performed by an expert physician blinded to clinical informa-
tion, including therapy. Another physician, blinded to hemodynamic
measurements, collected and recorded all clinical data of enrolled
patients and controls.
2.2. Carotid artery evaluation
Carotid atherosclerosis was assessed by an expert physician (D.T.)
using high-resolution B-mode ultrasonography equipped with a multi-
frequency linear probe. Carotid arteries were investigated in longitudi-
nal projections of both the left and right side, at the level of the
common carotid artery, of the bulb and of the internal carotid. Carotid
IMT was measured as the difference between a ﬁrst interface (lumen-
intima) and a second interface (media-adventitia), along the wall of
the common carotid artery, in a free section of plate, for 10 mm up-
stream and 10 mm downstream of their bifurcations. For each subject,
three measurements were made on both sides, projection in front,
side and rear, andweremade an average of themeasurements. A carot-
id plaquewas deﬁned the ﬁnding of a focal thickening of N1.3mmat the
level of the common carotid arteries and their bifurcations. The operator
assessed the intra-observer variability repeating in two different times
the carotid IMTmeasurements in ten IBD patients and ﬁve controls ran-
domly chosen. The concordance coefﬁcient between the intra-observer
evaluations was 0.97. The inter-observer evaluation was not calculated
because all measurements were performed by the same operator.
2.3. Pulse wave velocity assessment
Examinations were carried out by an expert physician (V.D.C.), after
15 min of rest, carefully following the directions given for a correct
standardization of the conditions of the subjects examined. Approxi-
mately every 2 min, blood pressure was checked at the level of the
brachial artery (DinamapProCare 100; GE Healthcare).
The values of the central pressures were recorded in a non-invasive
manner through the applanation tonometry (SphygmoCor; AtCor
Medical, Sydney, Australia). Carotid-femoral PWV was measured in
the supine position using the automatic device (SphygmoCor version
7.1) that measured the time delay between the rapid upstroke of the
carotid and femoral artery pulse waves. The distance between the two
arterial points was measured on the surface of the body using a tape
measure. PWV was calculated as the distance travelled by the arterial
pulsewave (meters) divided by the time delay between the two arterial
points (seconds), thus expressed as meters per second (m/s). The
“distance between the two arterial points” was measured using the
total distance between the carotid and femoral sites of measurement
[34,35].
PWV assessment has been repeated in two different times in ten IBD
patients andﬁve controls randomly chosen. The concordance coefﬁcient
between the intra-observer evaluations was 0.96. The inter-observer
evaluation was not calculated because all measurements were
performed by V.D.C.
2.4. Pulse wave analysis
Applanation tonometry was used to record radial arterial pressure
waveform continuously, and mean values of ≥2 screens of pulse
waves of good quality were used for analysis. On the basis of the
collected data, an averaged radial pressure waveform was generated
and a corresponding aortic pressure waveform and blood pressure
calculated by the validated transfer function. The aortic pressure wave-
formwas used to calculate the Aortic AIx (difference in height betweens of early atherosclerosis in patients with inﬂammatory bowel disease,
Table 1
Clinical-demographic and biochemical features of IBD patients and controls.
IBD Patients
(N = 68)
Controls
(N = 38)
P
Age (mean − SD) 31.6 (8.1) 30.4 (6.3) 0.395
Gender
Males 35 18 0.685
Females 33 20
Familial predisposition
for IBD
No 55 -
Yes 13 -
Familial predisposition for
Cardiovascular Disease
No 39 26 0.262
Yes 29 12
Smoking habit
No 43 25 0.994
Yes 24 14
BMI
Mean − SD 22.5 (3.8) 23.9 (4.4) 0.082
Hypertension
No 65 37 0.645
Yes 3 1
Diabetes
No 66 37 0.927
Yes 2 1
Carotid IMT mean (mm)
Right (range) 0.5 (0,2) 0.4 (0,1) 0.047
Left (range) 0.5 (0,1) 0.6 (0,7) 0.468
Carotid Plaque
No 60 34 0.129
Yes 8 1
AORTIC AIx (AP/PP)
Mean (SD) 16.4 (10.4) 11.0 (7.8) 0.004
AORTIC AIx (P2/P1) 121.9 (16.3) 110.5 (19.3) 0.002
Mean (SD)
PWV (cut-off) 8.7 (1.3) 8.0 (1.2) 0.006
(Mean − SD)
SBP 0.878
(Mean − SD) 118.1 (18.3) 117.6 (12.8)
DBP
(Mean − SD) 74.5 (13.8) 75.3 (11.6) 0.755
WBC (mean − SD) 7100 (2610) –
ESR (mean − SD) 14.3 (12.8) –
CRP (mean − SD) 8.4 (32.6) –
PLT (mean − SD) 283926 (94105) –
Hb (mean − SD) 13.4 (1.7) –
Total Cholesterol, (mean − SD) 159.9 (32.8) 176.9 (35.7) 0.015
HDL Chol 52.2 (15.4) 56.7 (18.1) 0.176
LDL Chol 90.1 (27.2) 103.9 (33.5) 0.023
Triglycerides (mean − SD) 93.4 (40.0) 81.1 (44.9) 0.152
3M. Cappello et al. / European Journal of Internal Medicine xxx (2016) xxx–xxxthe ﬁrst (P1) and second (P2) systolic peaks expressed as a percentage
of pulse pressure (PP) [36]).
2.5. Statistical analysis
Continuous variables were expressed asmean± standard deviation,
and categorical variables as absolute frequency and percentage. The
comparison between continuous variables was made by the Student's
t-test and categorical variables were analysed by using the chi-square
test. Multivariate logistic regression analysis was used to assess the
relationship between the use of 5-ASA and the arterial stiffness
parameters. Statistical signiﬁcance was reached when P was b0.05.
Data obtained were analysed using the software SPSS (Statistical
Package for Social Science) ver. 15.0.
3. Results
We enrolled 106 subjects: 68 IBD patients (males 51.5%), mean age
of 31.6 ± 8.1 years (range 17–45 years) and 38 healthy individuals'
age and sex matched as controls. Demographic, clinical and laboratory
features of IBD patients and controls are summarized in Table 1.
Among IBD patients, 45 (66%) had CD, of whom 22 (48%) had a
disease duration greater than 5 years, 9 (20%) showed a clinically active
disease; 23 (33%)were suffering fromUC, 8 (35%) of these had a disease
duration greater than 5 years and 3 showed a clinically active disease.
Overall,meandisease durationwas 5.0±4.3 years. Among IBDpatients,
13 (19.1%) had a family history of IBD. As for the traditional risk factors
for cardiovascular events, 16 (23.5%) patients were smokers; 9 (13%)
ex-smokers; 29 (42%) had a family history of cardiovascular events, 3
were hypertensive and 2 patients had diabetes mellitus, 21 had a BMI
greater than 25. Markers of inﬂammation, such as CRP and ESR, were
evaluated only in IBD patients.
IBD features of the study population are shown in Supplementary
Table. Nine out of 45 CD patients (22%) had an ileal localization, 71.1%
and 2.2% had ileo-colic and colic respectively, 6.7% had an upper diges-
tive tract involvement (stomach and/or duodenum and/or jejunum),
37.8%hadnot stricturing notﬁstulising behaviour, 35.5%had stricturing,
13.3% ﬁstulizing, 6.7% stricturing and ﬁstulizing and 6.7% had perianal
disease. Among 23 patients with UC, 34.8% had proctosigmoiditis,
47.8% left colitis and 17.4% pancolitis. Extra-intestinal manifestations
were present in 31% of CD patients and in 13% with UC. At the time of
recruitment, 62% of patients with CD were treated with mesalamine,
27% with steroids, 35.5% with immunosuppressants and 29% were on
biological therapy (inﬂiximab or adalimumab), while among the UC
patients 91.3% were takingmesalamine, 26% steroids, immunosuppres-
sants 30.4%, and 8.7% were on biologics (inﬂiximab or adalimumab).
3.1. Comparison between IBD patients and healthy controls
There were no statistically signiﬁcant differences between patients
and controls as concerns family history of cardiovascular events,
smoking habits, diabetes and hypertension. There was a trend toward
signiﬁcance in the distribution of body mass index values between
patients and controls (22 ± 3.8 versus 24 ± 4.4, P = 0.082). A
statistically signiﬁcant difference was found for the values of total
cholesterol (159, 9 ± 32, 8 mg/dl vs 176, 9 ± 35.7 mg/dl, P = 0.015)
and LDL-cholesterol (90, 1 ± 27.2 mg/dl vs 103, 9 ± 33.5, P = 0.023)
which were lower in IBD patients. There was no difference in lipid
proﬁle between CD and UC.
3.2. Hemodynamic measurements in IBD patients and controls
Table 1 presents the results regarding values of IMT and arterial
stiffness of carotid artery. The average carotid IMT was higher in
patients with IBD than in controls (0.5 ± 0.2 vs 0.4 ± 0.1, P = 0.047)
(Fig. 1), any statistically signiﬁcant difference in carotid IMT wasPlease cite this article as: Cappello M, et al, Increased expression of marker
Eur J Intern Med (2016), http://dx.doi.org/10.1016/j.ejim.2016.10.004found between subjects with CD and UC. The presence of a plaque
was observed in eight patients, while only in one control subject.
Regarding parameters related to arterial stiffness, PWV values were
signiﬁcantly higher in IBD patients as compared to controls (8.7±1.3 vs
8.0 ± 1.2, P = 0.006); values of Aortic AIx (AP/PP) were increased in
patients with IBD as compared with healthy controls (16.4 ± 10.4 vs
11 ± 7.8, P = 0.004), as well (See Figs. 2 and 3). Values of systolic and
diastolic BP were normal in both groups, patients and controls.
3.3. Impact of disease features and pharmacological therapy on
hemodynamic measurement
Regarding all hemodynamic measurements, no signiﬁcant
differences between patients with CD and UC have been shown
(Table 2). In addition, no signiﬁcant differences have been found
between values of IMT, PWV and Aortic Aix among IBD patients in
relation to disease duration and activity. In fact, although the Mayo
Score [32] and the Harvey Bradshaw Index [33] are indices widely
used in clinical trials, they do not really reﬂect the control of mucosals of early atherosclerosis in patients with inﬂammatory bowel disease,
Fig. 1. IMT values of IBD patients as compared with healthy controls.
Fig. 3. AIx values (AP/PP) of IBD patients as compared with healthy controls.
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scores. In addition, the absence of correlation between disease duration
and hemodynamic measurements was also conﬁrmed by linear
regression analysis. Age, was signiﬁcantly related to increasing values
of all hemodynamic parameters, as expected (Table 3).
Impact of pharmacological therapy was separately analysed, as
shown in Table 4.
A statistically signiﬁcant relationship between the use of 5-ASA and
stiffness parameters (Aortic Aix, AP/PP) was observed (18.2 ± 10.2 vs
11.9 ± 9.7, P = 0.021); further, this association was conﬁrmed in a
multivariate logistic regression analysis (OR 1.08, CI 95% 1.01–1.15,
P = 0.019); on the contrary, the same relationship could not be
demonstrated for the distribution of IMT and other arterial stiffness
values. Finally, the use of steroids, immunosuppressants and biologics
did not correlate with hemodynamic measurements.
4. Discussion
Our study explored the hypothesis of early onset atherosclerosis in
young patients with IBD, through the assessment of the prevalence of
increased IMT and of higher values of arterial stiffness, in comparison
to a group of healthy controls. We showed in a homogeneous cohort
of Mediterranean young IBD patients, as far as concerns ethnic origin,
amild increase in the values of carotid IMT and the alteration of both pa-
rameters exploring the elastic properties of the arterial wall (PWV and
Aortic AIx) compared to healthy controls, age and sex matched.Fig. 2. Comparison of PWV values of IBD patients and healthy controls.
Please cite this article as: Cappello M, et al, Increased expression of marker
Eur J Intern Med (2016), http://dx.doi.org/10.1016/j.ejim.2016.10.004Interestingly, in our patients the carotid IMT values, while showing
levels classiﬁable in the “so-called” normal range (IMT b 1.3 mm)
were signiﬁcantly higher than in healthy controls (P b 0.042). Our
data conﬁrm the results of most studies conducted in Mediterranean
area [27–30], though other studies, carried out in Israel obtained
opposite results [22–23]. We could speculate that ethnicity might
have an inﬂuence on the risk of atherogenesis, being higher in
population from Italy and Turkey, as compared with population from
Israel, even if, we do not have any genetic markers to support our
hypothesis.
Values of PWV and the Aortic AIx, such as the carotid IMT, were also
signiﬁcantly higher in our patients with IBD, although falling always
within the normal range (b12 mm/s for PWV) in agreement with the
results obtained by Zanoli [29,30]. Ozturk et al. found signiﬁcant in-
crease in PWV in a rather large sample but they were not able to
evidentiate a difference in IMT [31]. In our study, we assessed arterial
stiffness, not only by PWV, but also by central AIx. To our knowledge,
ours is the only study assessing the arterial stiffness both by PWV and
AIx in this clinical setting. In particular, central AIx respect to peripheral
AIx, represents an element that suggests an earlier impairment of the
elastic property of arterial wall and therefore it is likely to be considered
a more reliable marker of “elastic dysfunction” and index of early
atherosclerosis in these patients. Indeed, discrepant results of studies
investigating markers of sublinical atherosclerosis could also be related
to the different accuracy of vascular parameters in relation to the
progression of atherosclerosis. Regarding to this, ﬂow-mediated vasodi-
latation reﬂects early changes of the endothelium function, followed byTable 2
Clinical and haemodynamic assessment of IBD patients in relation to IBD type.
MC (45) UC (23) P
Age (mean − SD) 32.2 (7.3) 30.6 (9.7) 0.486
Gender (male) 20 (%) 15 (%) 0.105
Duration of disease N 5 years 22 (%) 8 (%) 0.268
Age ≥ 25 years 36 (%) 15 (%) 0.183
Extra-intestinal manifestations 14 (%) 3 (%) 0.094
Active disease 9 (20%) 10 (43.5%) 0.041
ESR (mean − SD) 15.5 (13.9) 12.0 (9.9) 0.299
CRP (mean − SD) 11.3 (39.8) 2.8 (4.2) 0.163
IMT carotid right (mean − SD) 0.5 (0.1) 0.5 (0.2) 0.490
IMT carotid left (mean − SD) 0.5 (0.1) 0.5 (0.1) 0.961
Aortic AIx (AP/PP) 16.8 (11.0) 15.6 (9.4) 0.656
Aortic AIx (P2/P1) 122.2 (17.4) 121.3 (14.4) 0.831
PWV (m/s) 8.6 (1.3) 9.1 (1.4) 0.136
SBP (mean − SD) 117.2 (20.3) 119.9 (13.9) 0.527
DBP (mean − SD) 72.6 (12.6) 78.2 (15.6) 0.115
Total cholesterol (mean-SD) 157.3 (31.5) 165 (35.4) 0.363
Triglycerides (mean-SD) 89.4 (33.4) 101.0 (50.6) 0.263
s of early atherosclerosis in patients with inﬂammatory bowel disease,
Table 3
Relationship between haemodynamic measurements and disease features (duration and activity) of IBD patients.
Age b 25 years Age N 25 years P No active disease Active disease P Disease b 5 years Disease N 5 years P
(17) (51) (49) (19) (38) (30)
Carotid IMT mean (mm)
Right (range) 0.5 (0.3) 0.5 (0.1) 0.934 0.5 (0.2) 0.5 (0.1) 0.879 0.5 (0.2) 0.5 (0.1) 0.708
Left (range) 0.4 (0.1) 0.5 (0.2) b0.001 0.5 (0.1) 0.6 (0.2) 0.172 0.5 (0.2) 0.5 (0.1) 0.513
CarotidPlaque
No 16 44 43 17 35 25
Yes 1 7 0.385 6 2 0.844 4 4 0.654
AORTIC AIx (AP/PP) 8.7 (9.4) 18.9 (9.5) b0.001 17.0 (10.9) 14.6 (9.0) 0.178 15.3 (10.0) 17.7 (10.9) 0.341
Mean
AORTIC AIx (P2/P1) 110.4 (11.6) 125.7 (15.9) 0.001 123.3 (17.1) 118.6 (13.4) 0.301 120.3 (14.7) 123.9 (18.2) 0.373
Mean (SD)
PWV (cut-off) 8.1 (1.1) 8.9 (1.3) 0.010 8.7 (1.2) 8.7 (1.4) 0.882 8.5 (1.4) 9.0 (1.2) 0.136
Mean (SD)
SBP 0.177 0.300
Mean (SD) 114.1 (11.3) 119.5 (20.0) 117.0 (15.9) 122.4 (24.4) 115.1 (13.5) 122.0 (22.7) 0.121
DBP
Mean (SD) 70.6 (15.4) 75.8 (13.1) 0.178 74.4 (13.7) 73.8 (14.3) 0.826 73.3 (14.2) 76.1 (13.3) 0.414
5M. Cappello et al. / European Journal of Internal Medicine xxx (2016) xxx–xxxstiffnessmeasures, whereas themean IMTmay be a late marker, so that
its detection requires a longer follow up.
Markers of early atherosclerosis were overrepresented in our IBD
patients, in spite of the low prevalence of traditional cardiovascular
risk factors. Indeed, in our study, IBD patients and control group did
not show differences in the prevalence of smoking, diabetes and
hypertension, and furthermore, body mass index values and total
cholesterol and LDL-cholesterol levels were lower in IBD patients than
in controls. This clinical scenario, deﬁned by Zanoli “the IBD paradox”
[30], has been already introduced in the epidemiological study carried
on by Yarur [16], in which 356 IBD patients and 712 controls have
been studied for a median of 53 months. In this study, the reported
incidence of developing coronary artery disease in the IBD group was
signiﬁcantly higher (2.85; 95% CI 1.82–4.46), even though the incidence
of smoking, hypertension, diabetes and overweight was low. It seems
that traditional and non-traditional risk factors, such as white blood
cell count, haemoglobin, ESR, CRP, markers of systemic chronic inﬂam-
mation, could have a different impact on the incidence of cardiovascular
events in IBD and non-IBD patients. Therefore, the key clinical question
is whether the incidence of cardiovascular events in these patients is
mainly due to early atherosclerosis per se (increasing of all stiffness
parameters) or to persistent inﬂammation, which could contribute to
the atherosclerotic process through the maintenance of endothelial
dysfunction. Indeed, IBD patients are carriers of a signiﬁcant inﬂamma-
tory background, as shown by altered level of CRP, and the pivotal role
of inﬂammation in the onset of atherosclerosis has been conﬁrmed byTable 4
Relationship between pharmacological therapy and haemodynamic measurements among IBD
No Steroids Steroids P No 5-ASA
(50) (18) (20)
Carotid IMT mean (mm)
Right (range) 0.5 (0.2) 0.5 (0.1) 0.552 0.5 (0.1)
Left (range) 0.5 (0.2) 0.5 (0.1) 0.787 0.5 (0.1)
Carotid Plaque
No 17 43 18
Yes 1 7 0.340 2
AORTIC AIx (AP/PP) 17.1 (10.6) 14.3 (9.9) 0.338 11.9 (9.7
Mean (SD)
AORTIC AIx (P2/P1) 123.1 (16.9) 118.3 (14.5) 0.287 114.8 (1
Mean (SD
PWV (cut-off) 8.8 (1.3) 8.4 (1.3) 0.258 8.3 (1.2)
Mean (SD
SBP
Mean (SD) 117.8 (16.2) 119.1 (23.7) 0.797 114.7 (1
DBP
Mean (SD) 75.0 (14.7) 73.1 (11.4) 0.619 71.1 (11
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Eur J Intern Med (2016), http://dx.doi.org/10.1016/j.ejim.2016.10.004previous studies, and has been also correlated with the level of pro-
inﬂammatory cytokines [36,37]. In addition, it has been also reported
that high levels of such cytokines, selectins and adhesion molecules
were strongly related to the “markers” of arterial stiffness in patients
suffering from cerebrovascular events [37,38]. Taken together, these
data suggest that inﬂammation not only is strictly related to markers
of arterial stiffness, but also is responsible of the raised atherogenic
risk of these patients and, thus of cardio and cerebrovascular events in
long-term exposed subjects.
In accordance with this hypothesis, Rungoe et coll [17], showed in
the Danish cohort study that long-term risk of cardiovascular event in
IBD patients was modiﬁed by treatment with 5-aminosalicilyc acids
(5-ASA) and other interventions reducing the inﬂammatory burden of
intestinal disease. In our study we could not demonstrate differences
in vascular parameters among patients treated with steroids, immuno-
modulators or biologics. A statistically signiﬁcant correlation has been
found only for patients treated with 5-ASA, who showed an increase
in central AIx. A possible explanation could be that 5-ASA is not enough
effective in the control of inﬂammation in these patients. The increased
values of AIx in patients on stable maintenance with 5-ASA only, are in
keeping with the results obtained by Zanoli et coll [30], showing that at
least one parameter related to aortic stiffness, PWV, did increase over
time in patients treated with salicylates as compared to those on long-
term treatment with immunomodulating drugs. These data support
the hypothesis of a need for a powerful anti-inﬂammatory intervention
in IBD for preventing atherosclerosis and its consequences. Indeed, thepatients.
5-ASA P No Imm/Bio Imm/Bio P
(48) (39) (29)
0.587
0.5 (0.2) 0.347 0.5 (0.1) 0.5 (0.2) 0.789
0.5 (0.2) 0.416 0.5 (0.2) 0.5 (0.1)
42 35 25
6 0.771 4 4 0.654
) 18.2 (10.2) 0.021 15.9 (8.8) 16.9 (12.4) 0.704
3.6) 124.8 (16.6) 0.019 121.1 (13.9) 123.0 (19.3) 0.652
8.9 (1.3) 0.096 8.6 (1.4) 8.9 (1.2) 0.349
8.4) 119.6 (18.3) 0.320 115.8 (17.6) 121.3 (19.1) 0.222
.0) 75.9 (14.7) 0.190 72.4 (12.7) 77.4 (14.8) 0.141
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role of 5-ASA in the maintenance of remission for its limited efﬁcacy
showed by randomized clinical trials and meta-analyses [40]. Though
being effective in the maintenance of remission of mild-to-moderate
UC and possibly effective in chemoprevention, in other indications the
role of 5-ASA is questioned and deﬁnitely not enough for the proper
control of inﬂammation in Crohn's Disease.
The effect of medications on vascular parameters has not been
conﬁrmed by Ozturk et al. [31] though this could be explained by a
more relevant proportion of UC patients in their cohort, thus on
maintenance therapy with 5-ASA, which in UC could lead to an
adequate control of inﬂammation.
Results of our cross-sectional study in agreement with the prospec-
tive, though median follow-up was limited to 3.4 years, pilot study of
Zanoli et coll [30], suggest the absence of a protective role of 5-ASA on
reducing cardiovascular risk. However, a simple association by chance,
because of the small sample size, cannot be discarded. The role of
5-ASA should be assessed in an interventional prospective trial on an
adequate patients sample and for an extended period of time. Since
most patients were on multiple therapies is not possible to exclude
positive or negative effect of the contemporary administration of two
or more drugs. A further conﬁrm of our results comes from the paper
of dos Santos and colleagues [41], who found that women with UC in
clinical remission still have a higher risk for development of atheroscle-
rosis compared to the controls, but “women treated with azathioprine
seem more protected than those treated only with aminosalicylates,
due to better regulation of the inﬂammatory process”.
This study may have some limitations. First, a larger number of
subjects could be necessary to perform with sufﬁcient power subgroup
analyses in patients with CD or UC, as well as in those with active
disease or in remission. Secondly, to endorse the role of inﬂammation,
a further control group of subjects with other chronic inﬂammatory dis-
orders such as rheumathoid arthritis or ankylosing spondylitis would
have been useful though difﬁcult to match especially for age. Published
data in the setting of rheumatologic disorders [42–43], including also a
recent paper of our group [44], conﬁrm the increased rate of early
alterations of elastic properties of the arterial wall in a cohort of patients
of the same ethnic origin. The single head-to-head comparison study
published so far on expression of atherosclerosis markers in intestinal
and rheumatological inﬂammatory disease, while conﬁrming higher
stiffness values in both conditions, points toward a major role of
traditional risk factors [45]. Thirdly, we did not investigate the possibil-
ity that a genetic predisposition that is not only limited to IBDmay be at
the base of the risk of cardiovascular disease and speciﬁcally to athero-
sclerosis in our cohort. Finally, we do not have a follow-up long enough
to evaluate the effect of immunomodulators on the incidence of
cardiovascular events. This requires a long time since, in our cohort,
until now, no cardio and/or cerebrovascular events has been observed.
We believe that a re-assessment of the hemodynamic parameters in
the follow-up of IBD patients at ﬁxed intervals (maybe three or ﬁve
years time), in relation to the course of disease (remission/relapse)
and pharmacological treatments, could provide better information to
discriminate the impact of immunosuppressive drugs and/or biologics
on the atherosclerotic process.
However, we believe our ﬁndings have clinical relevance because
contribute to expand previous knowledge about the pathogenic mech-
anisms underlying the high prevalence of cardiovascular morbidity
and mortality in patients with chronic systemic inﬂammatory disease.
In fact, there are consolidated evidences demonstrating that abnormal
arterial stiffness, reﬂecting the arterial wall modiﬁcations, is a powerful
and independent predictor for various adverse cardiovascular outcomes
[46–47]. In rheumatologic disease, it is a common practice to monitor
patients for the development of early atherosclerosis markers to assure
early recognition and management of cardiovascular disease. In IBD
evidence is still limited, mechanisms have not been fully elucidated
[46] and practice guidelines are not available and maybe it is stillPlease cite this article as: Cappello M, et al, Increased expression of marker
Eur J Intern Med (2016), http://dx.doi.org/10.1016/j.ejim.2016.10.004questionable if they are needed, as suggested in the recent review by
Rungoe et al. [48]. Wu and coworkers, however, in a very recent
meta-analysis support the clinical utility of markers of subclinical
atherosclerosis in the management of IBD patients [49]. We think our
work adds further information toward a modiﬁcation of standard
clinical practice. The absence of a protective role of 5-ASA, in spite of
its potential aspirin-like properties, could have clinical implications
meaning that reducing the burden of inﬂammation with earlier use of
more potent and potentially disease-modifying drugs, able to obtain
not only symptomatic improvement but also mucosal healing and
deep remission, is the key end-point of IBD management to improve
all outcomes. Management strategies in IBD should deﬁnitely look
“beyond symptoms” and aim to heal the mucosa in order to prevent
bowel damage, disability and maybe reverse cardiovascular risk [50].
In conclusion, in our study, we have shown the expression of
markers of early atherosclerosis in young patients with IBD. Larger
longitudinal studies are needed to better evaluate the correlation
between indices of subclinical atherosclerosis, and clinical, biochemical
signs of systemic inﬂammation and reliable markers for the healing of
the mucosa in subgroups exposed to different drugs in order to target
therapeutic interventions.
Supplementary data to this article can be found online at doi:10.
1016/j.ejim.2016.10.004.
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